Pharma-Bio Serv (PBSV) Change in Accured Expenses (2010 - 2026)

Pharma-Bio Serv (PBSV) has reported Change in Accured Expenses for 17 consecutive years, with -$546515.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses rose 8.58% year-over-year to -$546515.0; the trailing twelve-month figure through Apr 2026 stood at -$736605.0 (up 39.15% YoY), and the FY2025 full-year result was -$853006.0, up 29.35% from the prior year.
• Change in Accured Expenses eased to -$546515.0 in Q2 2026 per PBSV's latest filing, from -$148056.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $170854.0 in Q3 2023 and bottomed at -$597831.0 in Q2 2025.
• Historically, Change in Accured Expenses has averaged -$212887.1 across 5 years, with a median of -$200893.0 in 2023.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses jumped 305.27% in 2023, then tumbled 1618.45% in 2024.
• Over 5 years, Change in Accured Expenses stood at -$83385.0 in 2022, then sank by 285.47% to -$321427.0 in 2023, then soared by 83.03% to -$54545.0 in 2024, then surged by 245.93% to $79597.0 in 2025, then tumbled by 786.6% to -$546515.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$546515.0, -$148056.0, and $79597.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.